Literature DB >> 10960453

Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975.

A J Rodger1, S Roberts, A Lanigan, S Bowden, T Brown, N Crofts.   

Abstract

The aim of this study was to examine the long-term effects of hepatitis C virus (HCV) infection on a cohort of patients admitted with acute viral hepatitis from 1971 through 1975. The availability of stored sera from this time enabled testing to identify those who were anti-HCV-positive on admission. Sixteen percent (n = 238) of the cohort tested anti-HCV-positive. The unexposed group was selected from those who were anti-HCV-negative. Systematic approaches were used to locate the cohort and health outcomes assessed by a study-specific questionnaire and clinical, serological, virological, and biochemical assessment. Complete follow-up was achieved on 98 anti-HCV-positive individuals and 201 negatives. Injecting drug use (IDU) was the presumed route of infection. At a mean of 25 years' follow-up, 54% of the anti-HCV-positive group had evidence of chronic HCV infection (both anti-HCV- and HCV-RNA-positive); the remainder were HCV-RNA-negative. Sixty-nine percent of those chronically infected had elevated serum alanine transaminase (ALT) levels, but only 8% had progressed to overt cirrhosis, and no cases of hepatocellular carcinoma (HCC) were identified. In summary, anti-HCV-positive subjects were 8 times more likely to have died from suicide or drug overdose than from HCV-related disease. Anti-HCV-positive study subjects were at increased risk of liver-related pathology after 25 years' follow-up, but few had progressed to overt cirrhotic liver disease. Excess mortality in this group was not the result of liver disease. This suggests that the natural history of community-acquired HCV may be more benign than previously thought.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10960453     DOI: 10.1053/jhep.2000.9714

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  27 in total

1.  Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours.

Authors:  C Matheï; E Wollants; J Verbeeck; M Van Ranst; G Robaeys; P Van Damme; F Buntinx
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

2.  Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders.

Authors:  Myrna L Cozen; James C Ryan; Hui Shen; Ramsey Cheung; David E Kaplan; Christine Pocha; Norbert Brau; Ayse Aytaman; Warren N Schmidt; Marcos Pedrosa; Bhupinderjit S Anand; Kyong-Mi Chang; Timothy Morgan; Alexander Monto
Journal:  Dig Dis Sci       Date:  2016-04-08       Impact factor: 3.199

3.  Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment.

Authors:  K Weissenborn; J C Ennen; M Bokemeyer; B Ahl; U Wurster; H Tillmann; C Trebst; H Hecker; G Berding
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

Review 4.  Impact of new treatment options for hepatitis C virus infection in liver transplantation.

Authors:  Elda Righi; Angela Londero; Alessia Carnelutti; Umberto Baccarani; Matteo Bassetti
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

5.  Comparison of opiate-primary treatment seekers with and without alcohol use disorder.

Authors:  Bryan Hartzler; Dennis M Donovan; Zhen Huang
Journal:  J Subst Abuse Treat       Date:  2010-07-03

Review 6.  Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.

Authors:  Maria Kalafateli; Elena Buzzetti; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-03-13

7.  Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors.

Authors:  Anne M Guiltinan; Zhanna Kaidarova; Brian Custer; Jennie Orland; Angela Strollo; Sherri Cyrus; Michael P Busch; Edward L Murphy
Journal:  Am J Epidemiol       Date:  2008-01-17       Impact factor: 4.897

8.  Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study.

Authors:  Stuart C Gordon; Lois E Lamerato; Loralee B Rupp; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu Teshale; Fujie Xu; Joseph A Boscarino; Vinutha Vijayadeva; Mark A Schmidt; Nancy Oja-Tebbe; Mei Lu
Journal:  Am J Gastroenterol       Date:  2015-07-28       Impact factor: 10.864

Review 9.  The history of the "natural history" of hepatitis C (1968-2009).

Authors:  Leonard B Seeff
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828

10.  Impact of depressive symptoms and hepatic encephalopathy on health-related quality of life in cirrhotic hepatitis C patients.

Authors:  Katherine C Barboza; Lilian M Salinas; Farhad Sahebjam; Arun B Jesudian; Ilan L Weisberg; Samuel H Sigal
Journal:  Metab Brain Dis       Date:  2016-03-31       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.